Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $1.62, up 4.52% on the session, giving a market capitalisation of $967,159. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of 0.0%. Its beta of 1.13 implies it has historically moved more than the broad market.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Enveric Biosciences, Inc. is most often compared with the following Healthcare names: